Investigational therapy aims to close treatment gap in rare lung disease

Despite advancements in rare disease research, many patients still lack effective treatment options, including those with Nontuberculous Mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) — a chronic, debilitating condition that can cause permanent lung damage. One small biopharma company prepares to introduce a novel treatment approach. Learn more.